Therapeutic Advances in Gastroenterology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Endoscopic characteristics and usefulness of endoscopic dilatation of anastomotic stricture following pancreaticojejunostomy: case series and a review of the literature
We present three cases with recurrent pancreatitis induced by anastomotic stricture following pancreaticojejunostomy applied after pancreaticoduodenectomy. We successfully identified the anastomotic site and performed endoscopic dilatation of the anastomotic stricture, and pancreatitis has not recurred. We characterized endoscopic features of the anastomotic site, understanding of which is essential to identify the site, and investigated useful techniques to identify the site and perform cannulation for pancreatography. Furthermore, we showed the safety and usefulness of endoscopic dilatation for anastomotic stricture foll...
Source: Therapeutic Advances in Gastroenterology - October 20, 2016 Category: Gastroenterology Authors: Kida, A., Shirota, Y., Houdo, Y., Wakabayashi, T. Tags: Reviews Source Type: research

Hepatocellular adenoma: when and how to treat? Update of current evidence
Hepatocellular adenoma (HCA) is a rare, benign liver tumor. Discovery of this tumor is usually as an incidental finding, correlated with the use of oral contraceptives, or pregnancy. Treatment options have focused on conservative management for the straightforward, smaller lesions (<5 cm), with resection preferred for larger lesions (>5 cm) that pose a greater risk of hemorrhage or malignant progression. In recent years, a new molecular subclassification of HCA has been proposed, associated with characteristic morphological features and loss or increased expression of immunohistochemical markers. This subclassificati...
Source: Therapeutic Advances in Gastroenterology - October 20, 2016 Category: Gastroenterology Authors: Thomeer, M. G., Broker, M., Verheij, J., Doukas, M., Terkivatan, T., Bijdevaate, D., De Man, R. A., Moelker, A., IJzermans, J. N. Tags: Reviews Source Type: research

Direct-acting antivirals for the treatment of chronic hepatitis C in patients with chronic kidney disease
All-oral, direct-acting antivirals (DAAs) have significantly improved the efficacy and safety of chronic hepatitis C (CHC) treatment but their effectiveness and safety among patients with chronic kidney disease (CKD) remains poorly understood. Our aim was to assess the efficacy and safety of DAAs for treatment of CKD patients. The National Library of Medicine through PubMed was searched for studies evaluating the efficacy of DAAs for the treatment of patients with CKD stages 4 or 5, as defined by the Kidney Disease Outcomes Quality Initiative guidelines [i.e. glomerular filtration rate (GFR) 15–29 ml/min per 1.73 m2 ...
Source: Therapeutic Advances in Gastroenterology - October 20, 2016 Category: Gastroenterology Authors: Kohli, A., Alshati, A., Georgie, F., Manch, R., Gish, R. G. Tags: Reviews Source Type: research

The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care
Colorectal cancer has been ranked the third and second most prevalent of all cancers in men and women, respectively, and it represents the fourth most common cause of cancer deaths. In 2012, there were 1.4 million estimated cases of colorectal cancer worldwide, and 700,000 estimated deaths, which implies significant impact on public health, especially in economically-developed countries. In recent years, there has been an increase in the number of tumors, although this has been accompanied by decreased mortality, due to more appropriate and available information, earlier diagnosis, and improvements in treatment. Colorectal...
Source: Therapeutic Advances in Gastroenterology - October 20, 2016 Category: Gastroenterology Authors: De Rosa, M., Rega, D., Costabile, V., Duraturo, F., Niglio, A., Izzo, P., Pace, U., Delrio, P. Tags: Reviews Source Type: research

Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer
Malignant tumor cells are equipped with mechanisms that can help them escape the surveillance by host immune system. Immune checkpoint molecules can transduce coinhibitory signals to immunocompetent cells and exert immunosuppressive roles in antitumor immunity. Programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) are the two important checkpoint molecules with great potential in targeted cancer therapy. Several antibodies targeting PD-1 and PD-L1 have been approved for clinical use. In this review, we focus on the recent development of targeting PD-1 and PD-L1 in gastric cancer (GC) therapy. (Source: Therapeutic...
Source: Therapeutic Advances in Gastroenterology - October 20, 2016 Category: Gastroenterology Authors: Liu, X., Yang, Z., Latchoumanin, O., Qiao, L. Tags: Reviews Source Type: research

Vonoprazan-based therapy for Helicobacter pylori eradication: experience and clinical evidence
Stable suppression of gastric acid secretion is a crucial factor in Helicobacter pylori eradication. Vonoprazan is a potassium-competitive acid blocker recently approved for use in Japan. As vonoprazan has a long duration of action and causes rapid and strong inhibition of gastric acid secretion, it has gained clinical attention for treating erosive oesophagitis, peptic ulcers, and H. pylori infection. In this review, we discuss the recent knowledge regarding the safety and efficacy of vonoprazan, focusing on its use in H. pylori eradication. The latest literature and our clinical experience have shown that vonoprazan-base...
Source: Therapeutic Advances in Gastroenterology - October 20, 2016 Category: Gastroenterology Authors: Akazawa, Y., Fukuda, D., Fukuda, Y. Tags: Reviews Source Type: research

Helicobacter pylori and gastric acid: an intimate and reciprocal relationship
Helicobacter pylori (Hp) is the main cause of gastritis, peptic ulcer disease and gastric cancer. There are still unanswered questions related to the interaction between Hp and man, like what determines the susceptibility for the initial infection and the mechanisms for the carcinogenic effect. The initial infection seems to require a temporal gastric hypoacidity. For Hp to survive in the gastric mucous layer, some acidity is necessary. Hp itself is probably not directly carcinogenic. Only when inducing oxyntic mucosal inflammation and atrophy with hypoacidity, Hp predisposes for gastric cancer. Gastrin most likely plays a...
Source: Therapeutic Advances in Gastroenterology - October 20, 2016 Category: Gastroenterology Authors: Waldum, H. L., Kleveland, P. M., Sordal, O. F. Tags: Reviews Source Type: research

Impact of ornithine phenylacetate (OCR-002) in lowering plasma ammonia after upper gastrointestinal bleeding in cirrhotic patients
Conclusions: OP failed to significantly decrease plasma ammonia at the given doses (10 g/day). Higher doses of OP might be required in Child–Pugh A and B patients. OP appeared well tolerated. (Source: Therapeutic Advances in Gastroenterology)
Source: Therapeutic Advances in Gastroenterology - October 20, 2016 Category: Gastroenterology Authors: Ventura-Cots, M., Concepcion, M., Arranz, J. A., Simon-Talero, M., Torrens, M., Blanco-Grau, A., Fuentes, I., Sune, P., Alvarado-Tapias, E., Gely, C., Roman, E., Minguez, B., Soriano, G., Genesca, J., Cordoba, J. Tags: Original Research Source Type: research

The location of obstruction predicts stent occlusion in malignant gastric outlet obstruction
Conclusions: A distal location of malignant GOO was strongly predictive of stent occlusion, independent of stent angle. This may be due to longer and more complex distal obstructions, along with foreshortening of the stent during placement and tumor infiltration. If replicated, these results will have implications for endoscopic practice and future device development. (Source: Therapeutic Advances in Gastroenterology)
Source: Therapeutic Advances in Gastroenterology - October 20, 2016 Category: Gastroenterology Authors: Grunwald, D., Cohen, J., Bartley, A., Sheridan, J., Chuttani, R., Sawhney, M. S., Pleskow, D. K., Berzin, T. M., Mizrahi, M. Tags: Original Research Source Type: research

Prediagnosis aspirin use and outcomes in a prospective cohort of esophageal cancer patients
Conclusions: In our cohort of esophageal cancer patients, prediagnosis aspirin use was not associated with all-cause or cancer-specific mortality. However, risk of interval metastatic disease was increased among those who took aspirin regularly prediagnosis. Future studies are warranted to assess whether aspirin influences the molecular characteristics of esophageal tumors, with potential prognostic and therapeutic implications. (Source: Therapeutic Advances in Gastroenterology)
Source: Therapeutic Advances in Gastroenterology - October 20, 2016 Category: Gastroenterology Authors: Araujo, J. L., Altorki, N. K., Sonett, J. R., Rodriguez, A., Sungur-Stasik, K., Spinelli, C. F., Neugut, A. I., Abrams, J. A. Tags: Original Research Source Type: research

Usefulness of spectral computed tomography for evaluation of intestinal activity and severity in ileocolonic Crohns disease
Conclusions: Compared with conventional CT, spectral CT had higher accuracy in detecting intestinal activity and severity of CD, which could be an alternative choice in evaluation of CD. (Source: Therapeutic Advances in Gastroenterology)
Source: Therapeutic Advances in Gastroenterology - October 20, 2016 Category: Gastroenterology Authors: Peng, J. C., Feng, Q., Zhu, J., Shen, J., Qiao, Y. Q., Xu, J. R., Ran, Z. H. Tags: Original Research Source Type: research

Bioavailability, safety, and pharmacodynamics of delayed-release dexlansoprazole administered as two 30 mg orally disintegrating tablets or one 60 mg capsule
Conclusions: While systemic exposure (AUC) was 25% lower with ODT, peak concentrations (Cmax) after administration of two dexlansoprazole 30 mg ODTs and one 60 mg capsule were similar. The 24-hour intragastric pH control after administration of two dexlansoprazole 30 mg ODTs was equivalent to one dexlansoprazole 60 mg capsule. Both ODT and capsule were well tolerated. (Source: Therapeutic Advances in Gastroenterology)
Source: Therapeutic Advances in Gastroenterology - October 20, 2016 Category: Gastroenterology Authors: Kukulka, M., Nudurupati, S., Perez, M. C. Tags: Original Research Source Type: research

Pharmacokinetics and pharmacodynamics of an orally disintegrating tablet formulation of dexlansoprazole
Conclusions: Administration of dexlansoprazole 30 mg ODT or 30 mg capsule provided equivalent plasma exposure when either was administered as a single dose or as once daily doses for 5 days. Pharmacodynamic equivalence between the two formulations was demonstrated by similar intragastric pH parameters on both day 1 and day 5. No effect of day on dexlansoprazole pharmacokinetics was observed. Dexlansoprazole ODT and dexlansoprazole capsule were both well tolerated. (Source: Therapeutic Advances in Gastroenterology)
Source: Therapeutic Advances in Gastroenterology - October 20, 2016 Category: Gastroenterology Authors: Kukulka, M., Nudurupati, S., Perez, M. C. Tags: Original Research Source Type: research

The mucosal microbiota in a young child with severe non-Helicobacter gastritis
(Source: Therapeutic Advances in Gastroenterology)
Source: Therapeutic Advances in Gastroenterology - August 7, 2016 Category: Gastroenterology Authors: Preidis, G. A., Luna, R. A., Hollister, E. B., Schady, D., Gao, C., Finegold, M. J., Versalovic, J., Shulman, R. J. Tags: Letters to the Editor Source Type: research

Safety and efficacy of Vonoprazan-based triple therapy against Helicobacter pylori infection: A single-center experience with 1118 patients
(Source: Therapeutic Advances in Gastroenterology)
Source: Therapeutic Advances in Gastroenterology - August 7, 2016 Category: Gastroenterology Authors: Fukuda, D., Akazawa, Y., Takeshima, F., Nakao, K., Fukuda, Y. Tags: Letters to the Editor Source Type: research